LENZ Therapeutics Unveils Consumer Campaign for VIZZ Eye Drops
San Diego, January 14, 2026 – LENZ Therapeutics, Inc. announced the launch of its “Make it VIZZable” consumer campaign today, featuring actress and producer Sarah Jessica Parker as the brand ambassador for VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia. The campaign highlights VIZZ as a once-daily alternative to reading glasses, with nationwide availability and free samples through eye care professionals.
Campaign Highlights and Product Launch
The “Make it VIZZable” campaign showcases Parker’s personal experience with age-related blurry near vision, demonstrating how VIZZ provides clear near vision for up to 10 hours. VIZZ, approved by the FDA in August 2025, achieved strong results in Phase 3 CLARITY trials, where 93 percent of participants reached 20/40 or better near vision within 30 minutes. Launched commercially in October 2025, VIZZ generated approximately $1.6 million in net product revenue in Q4 2025, with over 20,000 prescriptions filled and more than 6,500 unique prescribing eye care professionals, over 55 percent of whom prescribed multiple times.
Eef Schimmelpennink, president and CEO of LENZ Therapeutics, stated, “We are proud of the strong execution in our first quarter of launch, establishing awareness and confidence among eye care professionals. With Sarah Jessica Parker, we look forward to launching the VIZZ direct-to-consumer campaign this quarter.” The company also announced its fourth commercialization partnership for VIZZ outside the United States, with Lunatus in the Middle East, including upfront and milestone payments.
Key Facts / Stats
| Metric | Details |
|---|---|
| VIZZ Q4 2025 Net Revenue | $1.6 million |
| Prescriptions Filled (Q4 2025) | Over 20,000 |
| Unique Prescribing ECPs | More than 6,500 |
| CLARITY Trial Responder Rate (3-lines improvement at 3 hours) | 71 percent |
| Pro Forma Cash Position (September 30, 2025) | $324 million |
Frequently Asked Questions
What is VIZZ and how does it work?
VIZZ (aceclidine ophthalmic solution) 1.44 percent is a once-daily eye drop that treats presbyopia by contracting the iris sphincter muscle to create a pinhole effect, extending depth of focus for near vision without causing a myopic shift. It provides improvement within 30 minutes and lasts up to 10 hours.
Is VIZZ available now?
Yes, VIZZ is available nationwide by prescription through eye care professionals. Free samples can be requested via VIZZ.com or participating doctors.
What are the common side effects of VIZZ?
The most common adverse reactions include instillation site irritation, visual impairment, and hyperemia, which are typically mild and transient. No serious treatment-related adverse events were reported in trials.